ImmunoGen cancer treatment application gets another chance
29-03-2022
Takeda Oncology offices based in Boston, Massachusetts
Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate (ADC) technology to develop and commercialise cancer drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda, ImmunoGen, M&A, Kadcyla, cancer
